PHS
TGTX icon

PFM Health Sciences’s TG Therapeutics TGTX Stock Holding History

PFM Health Sciences’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-98,674
Closed -$2.97M – 90
2024
Q4 		$2.97M Sell
98,674
-134,736
-58% -$3.87M 0.18% 65
2024
Q3 		$5.46M Buy
+233,410
New +$5.1M 0.31% 51

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PFM Health Sciences's TGTX Position: Q1 2025 in Review

PFM Health Sciences sold out of TG Therapeutics (TGTX) in Q1 2025, closing a stake of 98,674 shares — an estimated $2.97M sold.

PFM Health Sciences first reported a position in TGTX in Q3 2024 and held it in 2 quarters. The position peaked at $5.46M in Q3 2024. 376 funds tracked by Wall St. Rank hold TGTX as of Q1 2025.

  • PFM Health Sciences reported no remaining TG Therapeutics position as of Q1 2025 after selling out during the quarter.
  • PFM Health Sciences sold 98,674 TG Therapeutics shares in Q1 2025, an estimated $2.97M.
  • PFM Health Sciences first reported a position in TG Therapeutics in Q3 2024 and held it in 2 quarters.
  • PFM Health Sciences's TG Therapeutics position peaked at $5.46M in Q3 2024.
  • 376 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2025.

Based on PFM Health Sciences's 13F filing for Q1 2025, filed 15 May 2025.